Actavis restructures, appointing industry veterans to lead US Specialty Brands business units
US generics and specialty drugmaker Actavis (NYSE: ACT) has announced an updated business structure for its US Specialty Brands business designed to maximize the company's newly-strengthened position in key therapeutic areas and position it for continued long-term growth.
Under its new structure, Actavis' US Specialty Brands business has been refocused as four business units - Women's Health, Urology/Gastroenterology (GI), Dermatology/Established Brands and Business Operations.
The company has appointed Herm Cukier (who joins from Bayer) to lead the US Specialty Brands Women's Healthcare category, Charles Sabino Jr (formerly with Aptalis Pharma), to lead the US Specialty Brands Urology and GI therapeutic category, and Thomas Griffin Jr, to lead the Business Operations team.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze